Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04064515 · ClinicalTrials.gov registry record
CTCs in Cervix Cancer
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 4
- Enrollment target
NCT04064515 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 4 participants.
The verdict
NCT04064515 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 4 participants
- Enrollment target
Study Summary
This study is a validation study to confirm the ability of Telomescan OBP-401 to identify CTCs in patients with HPV 16 / 18 associated cervical cancer. CTCs identified will be tested for the presence of the HPV 16 / 18 E6 protein, confirming a cervical cancer origin.
Interventions
- DIAGNOSTIC_TEST Blood Assayed for CTCs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-03-02 |
| Est. Completion | 2020-04-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04064515
The ClinicalTrials.gov registry entry for NCT04064515 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood Assayed for CTCs is the first listed.
NCT04064515 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04064515 about?
NCT04064515 is a clinical study titled "CTCs in Cervix Cancer". This study is a validation study to confirm the ability of Telomescan OBP-401 to identify CTCs in patients with HPV 16 / 18 associated cervical cancer. CTCs identified will be tested for the presence of the HPV 16 / 18 E6 protein, confirming a cervical cancer origin.
What is the current status of trial NCT04064515?
This trial is currently completed. The enrollment target is 4 participants. The study started on 2020-03-02. Estimated completion is 2020-04-23.
What interventions are being tested in trial NCT04064515?
The interventions under investigation include: Blood Assayed for CTCs (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04064515?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.